The Russian vaccine is now part of India’s vaccination campaign
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the launch of vaccination with the Russian Sputnik V vaccine against coronavirus in India.
Sputnik V has become the first foreign-made vaccine that is used in India contributing to the world’s largest COVID-19 vaccination campaign.
Inoculations with Sputnik V in Hyderabad followed the arrival of the first batch of the vaccine in India on May 1, 2021. The second batch of Sputnik V is expected to arrive in India by the end of the week.
Sputnik V was approved for use in India on April 12, 2021, and granted an emergency use authorization. India is the leading production hub for Sputnik V. RDIF has reached agreements with the leading pharmaceutical companies in the country (Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech) aimed at the production of more than 850 million doses per year.
To date, Sputnik V is registered in 65 countries with a total population of over 3.2 billion people. Post-vaccination studies in a number of countries demonstrate that Sputnik V is the safest and most effective vaccine against coronavirus. Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.
Kirill Dmitriev, CEO, Russian Direct Investment Fund, said, “Sputnik V is the first foreign-made vaccine used in India. RDIF stands ready to support our partners in India to launch a full-scale vaccination with Sputnik V as soon as possible. The safe and effective Russian vaccine, which to date is authorized in 65 countries, will make an important contribution in upscaling the vaccination in India and bringing down the number of cases.”
